A Phase 2 #ClinicalTrial identified potential reasons for high recurrence rates in #AggressiveProstateCancer and suggests #TargetedTherapy as a hopeful treatment option.
#ProstateCancer #Biomarkers #ProstateCancerTreatment #Niraparib #ASCO25
0
0
0
0